14.27

6.12% -0.93

After Hours: 14.27

Apollomics Inc (APLM)

Overview News Price History Why APLM Down? Discussions Forecast

Apollomics Inc stock is traded at $14.27, with a volume of 5,062. It is down -6.12% in the last 24 hours and down -28.29% over the past month. Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Previous Close:

$15.20

Open:

$14.51

24h Volume:

5,062

Relative Volume:

0.45

Market Cap:

$30.64M

Revenue:

Net Income/Loss:

$-31.19M

P/E Ratio:

-0.5046

EPS:

-28.2788

Net Cash Flow:

$-28.76M

1W Performance:

-7.34%

1M Performance:

-28.29%

6M Performance:

-26.82%

1Y Performance:

+157.12%

1-Day Range:

$14.26

$14.51

1-Week Range:

$13.00

$15.96

52-Week Range:

$3.659

$42.12

Apollomics Inc Stock (APLM) Company Profile

Name

Apollomics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-04-02

Latest SEC Filings

APLM's Discussions on Twitter

Compare APLM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APLM Apollomics Inc	14.27	32.64M	0	-31.19M	-28.76M	-28.28
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Apollomics Inc Stock (APLM) Latest News

Apr 14, 2026

[Form 3/A] Apollomics Inc. Amended Initial Statement of Beneficial Ownership - Stock Titan

Apr 14, 2026

Apollomics (APLM) director Jan Chen-Huan reports 1,000 RSUs and 1,000 shares - Stock Titan

Apr 14, 2026

Apollomics (APLM) CFO details 20,000 RSUs and 15,900 shares in Form 3/A - Stock Titan

Apr 14, 2026

Apollomics (ticker: APLM) CEO details direct and indirect share stakes - Stock Titan

Apr 14, 2026

Apollomics (APLM) director discloses 1,000 restricted stock units award - Stock Titan

Apr 14, 2026

Apollomics (APLM) COO details RSU grants and Maxpro warrant stakes - Stock Titan

Apr 14, 2026

Apollomics (APLM) director Huang Ya-Chi details RSU vesting and share holdings - Stock Titan

Apr 14, 2026

Apr 13, 2026

Tech Rally: Does Apollomics Inc Equity Warrant have pricing power2026 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn

Apr 13, 2026

Market Outlook: Is Apollomics Inc in a consolidation phase2026 Bull vs Bear & AI Optimized Trading Strategy Guides - baoquankhu1.vn

Apr 13, 2026

Bear Alert: Can Apollomics Inc stock outperform in a bear marketWeekly Stock Analysis & Safe Investment Capital Preservation Plans - baoquankhu1.vn

Apr 13, 2026

Bond Watch: Can Apollomics Inc Equity Warrant expand its profit marginsEarnings Miss & Smart Swing Trading Techniques - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Aug Wrap: Will Apollomics Inc Equity Warrant outperform the market in YEARJobs Report & Long Hold Capital Preservation Tips - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Risk Off: Is Apollomics Inc attractive at current valuation2026 Analyst Calls & Long-Term Capital Growth Ideas - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026